Vertex Pharmaceuticals (VRTX) said Friday it has made a reimbursement agreement with National Health Service England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy.
The reimbursement agreement coincides with the UK National Institute for Health and Care Excellence recommending Casgevy's use by the NHS, the company said.
Administration of the therapy requires experience in stem cell transplantation, and Vertex said it is working with hospitals to establish treatment centers.
Shares of the company were up more than 8% in Friday's premarket activity.
Price: 475.00, Change: +36.60, Percent Change: +8.35
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。